Industry Insight | ​In Vivo CAR-T Gains Momentum as Early Clinical Data Show Promise in Lymphoma

The cell and gene therapy (CGT) field reached another important milestone this month as early clinical data from an investigational in vivo CAR-T therapy demonstrated encouraging results in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).

Recently released Phase 1 data from LB2501, an in vivo CD19/CD20 dual-targeting CAR-T candidate developed by Legend Biotech, showed promising clinical activity in heavily pretreated lymphoma patients. Among six patients treated at the higher dose level, all achieved an objective response, with five patients achieving a complete response. No dose-limiting toxicities, serious adverse events, or treatment-related deaths were reported.

Photo by Adam Bezer on Unsplash

Unlike conventional CAR-T therapies, which require collection, genetic modification, expansion, and reinfusion of a patient's T cells, LB2501 is designed to generate CAR-T cells directly within the patient through a single intravenous infusion. This approach has the potential to eliminate complex ex vivo manufacturing steps and significantly shorten treatment timelines.

The results add to growing industry enthusiasm surrounding in vivo CAR-T technology, which many view as one of the most promising next-generation cell therapy approaches. By simplifying manufacturing and enabling an off-the-shelf treatment model, in vivo CAR-T therapies could potentially improve patient access while reducing production complexity and costs.

For the broader CGT industry, these findings highlight an important trend: innovation is increasingly focused not only on therapeutic efficacy but also on improving scalability, accessibility, and manufacturing efficiency. As more in vivo CAR-T programs advance into clinical development, the demand for robust vector production, process development, analytical testing, and scalable manufacturing solutions is expected to grow.

Photo by CDC on Unsplash

At Hillgene, we believe the evolution of in vivo cell therapies underscores the importance of platform-based development and manufacturing. As next-generation CGT products move toward broader clinical adoption, reliable production systems and scalable process solutions will play a critical role in accelerating the journey from research to patients.

While the current data remain preliminary and longer-term follow-up will be needed, the results represent another encouraging step forward for in vivo CAR-T development and reinforce its potential to reshape the future landscape of cell therapy.

Sources:

* Legend Biotech Phase 1 LB2501 announcement (EHA 2026)

* Reuters, June 2026

* BioPharma Dive, June 2026